Plain-English translation of NCT06607419 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This clinical trial is testing a medication called to treat children with a type of blood cancer (B-cell leukemia) who have not responded adequately to standard chemotherapy alone. The trial will measure whether adding this medication helps eliminate remaining leukemia cells that are detected in bone marrow samples. If successful, this treatment could offer a better path forward for children who need more powerful therapies.
Some children with this type of leukemia don't respond well enough to chemotherapy alone, meaning cancer cells remain even after initial treatment. Researchers want to see if this medication—which works differently than chemotherapy—can more effectively clean up these remaining cells and improve outcomes for these children.
You likely qualify if…
You likely don't qualify if…
If you are selected for this trial, you will receive 14 days of the new medication through an IV (intravenous line). Before and after your treatment, doctors will take bone marrow samples to check how well the medication is working by looking for remaining leukemia cells. The study will compare your results to outcomes from other children treated with standard approaches to see if this new medication is more effective.
AI-generated summary from trial data · Jun 9, 2026 · Not medical advice
China